
Episode #61
Canadian Expert discussion on the treatment and management considerations for MIBC treatment regimens
<h2>Episode Notes</h2><p>Podcast Host Disclosures:</p><p>Dr. Black has received honoraria from AbbVie, Astellas Pharma, AstraZeneca, Bayer, Biosyent, Bristol- Myers Squibb, EMD-Serono, Ferring, Janssen Oncology, Merck, Nanology, Nonagen, Pfizer, Prokarium, Protara, QED, Roche Canada, Sanofi Canada, STIMIT, Urogen Pharma and Verity</p><p>Dr. Lalani has received honoraria from AbbVie, Astellas, AstraZeneca, Bayer, BMS, Eisai, EMD Serono, Ipsen, Janssen, McKesson, Merck, Novartis, Pfizer, Roche, TerSera. Funding for clinical trials directed to institutions from BMS (Inst), BioCanRx (Inst), Novartis (Inst), Roche (Inst), Ipsen (Inst), EMD Serrono (Inst).</p><p>Accreditation:</p><p>This podcast was accredited by...

